申请人:TAIHO PHARMACEUTICAL CO., LTD.
公开号:US20160340353A1
公开(公告)日:2016-11-24
Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis.
An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same:
where R
1
to R
4
, m and n have the same meanings as those defined in the description.